Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 2 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Kodiak Sciences Inc. has 4 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 3 distinct examiners across 3 art units, showing a distributed workload with one examiner handling more than one pending matter.
LOCKARD, JON MCCLELLAND is the busiest examiner, with 2 pending matters. Those matters provide the clearest opportunity for coordinated review, while the other assignments require separate examiner and art-unit analysis.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LOCKARD, JON MCCLELLAND | 2 | 74.4% | +27.4% |
| LOUNTOS, GEORGE THEMISTOCLIS | 1 | 57.1% | +60.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18166755 | METHODS OF PURIFYING A PRODUCT | LOUNTOS, GEORGE THEMISTOCLIS | 46d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16795450 | DUAL PDGF/VEGF ANTAGONISTS | LOCKARD, JON MCCLELLAND | 72d overdue |
| 18166755 | METHODS OF PURIFYING A PRODUCT | LOUNTOS, GEORGE THEMISTOCLIS | 46d |
| 18555122 | METHODS OF TREATING AN EYE DISORDER | LOCKARD, JON MCCLELLAND | — |
| Art Unit | Apps |
|---|---|
| 1647 | 2 |
| 1652 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18555122 | METHODS OF TREATING AN EYE DISORDER | LOCKARD, JON MCCLELLAND | 1647 | §102§112DP | Non-Final OA | — | Pending | Oct 12, 2023 |
| 18166755 | METHODS OF PURIFYING A PRODUCT | LOUNTOS, GEORGE THEMISTOCLIS | 1652 | §102§103§112 | Final Rejection | 46d | Pending | Feb 09, 2023 |
| 16795450 | DUAL PDGF/VEGF ANTAGONISTS | LOCKARD, JON MCCLELLAND | 1647 | §112 | Non-Final OA | 72d overdue | Pending | Feb 19, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKodiak Sciences Inc. has 3 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Jon Mcclelland Lockard has the most, with 2 of Kodiak Sciences Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
